Abstract Details

Title Safety of Alemtuzumab After Exposure to Chemotherapeutic Agents in Patients with Multiple Sclerosis - Experience of a single MS center

Topic Multiple Sclerosis

Presentation(s) P5 - (-)

Poster/Presentation
Number 367

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Daniela A. Pimentel Maldonado, MD, MSCR (U.S. Food and Drug Administration) PRESENTER	Dr. Pimentel Maldonado has nothing to disclose.
Oleg Y. Yerstein, MD	Dr. Yerstein has nothing to disclose.
	No disclosure on file
Raffaella Umeton, MD, PhD, MMSc	Dr. Umeton has nothing to disclose.
	No disclosure on file
Carolina Ionete, MD (UMass Memorial)	Dr. Ionete has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Ionete has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Zenas. Dr. Ionete has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. The institution of Dr. Ionete has received research support from Genetech. The institution of Dr. Ionete has received research support from NIH.

��ɫ��